Aeglea’s Rare Disease Asset Succeeds At Phase III, In Line To Become First Product

BLA Filing Expected Next Year

 
• By Ayisha Sharma
Child On Bed With IV
Pegzilarginase Was Given Intravenously To Children Aged Two And Up. • Source: Alamy

More from Clinical Trials

More from R&D